Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2019-06-25 Report Publication Anno…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
XVIVO Perfusion tidigarelägger datum för rapportering av Bokslutskommuniké 2019 till den 30:e januari 2020.
Report Publication Announcement Classification · 98% confidence The document is a short press release (1905 characters) dated June 25, 2019. The headline explicitly states that the company is 'tidigarelägger datum för rapportering av Bokslutskommuniké 2019' (preponing the date for reporting the Year-End Report 2019) to January 30, 2020. This is not the actual financial report itself, but an announcement about the timing of a future report release. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or timing of a report should be classified as a Report Publication Announcement (RPA).
2019-06-25 Swedish
Change in number of shares and votes in XVIVO Perfusion
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release titled "Change in number of shares and votes in XVIVO Perfusion" dated May 31, 2019. It explicitly states that the number of shares increased due to warrants being exercised, resulting in a new total share count. This directly relates to changes in the company's capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate category, as it covers announcements regarding new share issues or capital changes. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a transaction in own shares (POS) which usually implies buybacks or sales, although this is related to warrant exercise leading to new shares.
2019-05-31 English
Förändring av antalet aktier och röster i XVIVO Perfusion
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated May 31, 2019, titled "Förändring av antalet aktier och röster i XVIVO Perfusion" (Change in the number of shares and votes in XVIVO Perfusion). It explicitly states that the number of shares and votes increased due to the exercise of warrants under an incentive program, resulting in a new total share count. This directly relates to changes in the company's capital structure or share count. This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers new share issues and capital changes. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a transaction in own shares (POS) as it results from an incentive program exercise, leading to an increase in outstanding shares.
2019-05-31 Swedish
XVIVO har erhållit klartecken från läkemedelsverket för kliniska studier med bolagets nya produkter för hjärtpreservation
Legal Proceedings Report Classification · 99% confidence The document is a press release dated May 15, 2019, announcing that XVIVO has received approval from the Swedish Medical Products Agency ('läkemedelsverket') to commence clinical studies for its heart preservation products. This announcement details regulatory progress, study design (randomized, multi-country), and the significance of the development for future regulatory approval in Europe. It is not a full financial report (10-K or IR), an earnings release (ER), a transcript (CT), or a formal regulatory filing like a DVA or DIRS. Since it is an announcement regarding a significant operational/regulatory milestone that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for important, non-standard announcements, or potentially a general 'LTR' if viewed as a regulatory update, but RNS is broader for general press releases about regulatory milestones. Given the context of a press release announcing regulatory clearance for clinical trials, RNS is the most appropriate general regulatory announcement category.
2019-05-15 Swedish
XVIVO has received approval from the Swedish MPA to begin clinical studies with the company's new products for heart preservation
Regulatory Filings Classification · 98% confidence The document is explicitly titled as a "Press release" announcing that XVIVO has received approval from the Swedish Medical Products Agency (MPA) to begin clinical studies for its heart preservation products. This announcement details regulatory progress, study plans, and future regulatory submission goals. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement. Since it is a specific regulatory/operational update that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), and it is a formal announcement, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-financial, non-meeting related corporate news, or potentially a Legal/Regulatory update (LTR) given the involvement of the MPA. However, RNS is the most appropriate fallback for general regulatory news releases that aren't explicitly about insider trading, dividends, or capital structure changes. Given the context of regulatory approval for a clinical study, RNS is the best fit among the provided options, as it is a significant regulatory event announcement.
2019-05-15 English
First XPS™ sold to Canada
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press release" and announces a specific business event: the first sale of the XPS™ system to a Canadian clinic. It includes a date (May 3, 2019), quotes from the CEO, contact information for the CFO and CEO, and concludes with a statement that the information is "obliged to make public pursuant to the EU Market Abuse Regulation." This structure strongly indicates a general regulatory announcement or press release regarding a material event, rather than a comprehensive financial report (like 10-K or IR), a specific shareholder vote result (DVA), or a management change (MANG). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIV, CAP, or M&A), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (3647 chars), supporting the idea that it is an announcement rather than the full report itself.
2019-05-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.